Cheap Drug Reduces Insulin Dosage for Type 1 Diabetes Patients

A low-cost medication commonly used for type 2 diabetes may help individuals with type 1 diabetes reduce their insulin requirements, according to recent research findings.

The medication in question is dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor that works by helping the kidneys remove excess glucose from the bloodstream through urine. While primarily approved for type 2 diabetes, emerging evidence suggests it may offer adjunctive benefits for some people living with type 1 diabetes when used alongside insulin therapy.

A clinical study published in a peer-reviewed medical journal found that participants with type 1 diabetes who took dapagliflozin daily experienced a modest but statistically significant reduction in their total daily insulin dose over a 24-week period. On average, insulin requirements decreased by approximately 10% compared to baseline levels, without a corresponding increase in severe hypoglycemic events when patients were properly monitored.

Researchers noted that the reduction in insulin use was accompanied by improvements in glycemic variability and modest weight loss among participants. These effects are attributed to the drug’s mechanism of promoting glucosuria, which lowers blood glucose levels independently of insulin action.

Despite these promising observations, medical experts caution that SGLT2 inhibitors like dapagliflozin are not without risks, particularly for individuals with type 1 diabetes. The primary concern is an increased risk of diabetic ketoacidosis (DKA), a serious metabolic condition that can occur even when blood sugar levels are not markedly elevated — a phenomenon known as euglycemic DKA.

Due to this risk, regulatory agencies in several countries have not approved SGLT2 inhibitors for standalone use in type 1 diabetes. However, some specialists may consider off-label use in carefully selected patients under close medical supervision, including frequent ketone monitoring and patient education on DKA prevention.

Endocrinologists emphasize that any consideration of adding such medication to a type 1 diabetes regimen should involve a thorough risk-benefit discussion with a qualified healthcare provider. Factors such as hypoglycemia unawareness, history of DKA, renal function, and adherence to monitoring protocols must be evaluated before initiating therapy.

Ongoing research continues to investigate the long-term safety and efficacy of SGLT2 inhibitors in type 1 diabetes populations. Larger, longer-term trials are needed to determine whether the modest reductions in insulin use translate into meaningful improvements in diabetes-related complications, quality of life, or healthcare burden over time.

For now, dapagliflozin remains a promising but investigational adjunct in type 1 diabetes management. Patients are advised not to alter their prescribed treatment regimen without consulting their diabetes care team, as improper use could lead to serious health complications.